Valuation: Ionis Pharmaceuticals, Inc.

Market Cap 13.52B 11.84B 10.9B 10.12B 19.22B 1,289B 19.48B 131B 50.8B 633B 50.77B 49.65B 2,195B P/E 2026 *
-22.7x
P/E 2027 * -65x
Enterprise Value 13.3B 11.65B 10.73B 9.96B 18.91B 1,269B 19.16B 128B 49.97B 623B 49.94B 48.85B 2,159B EV / Sales 2026 *
14.9x
EV / Sales 2027 * 8.89x
Free-Float
99.09%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Ionis Pharmaceuticals, Inc.

1 day+2.26%
1 week+3.62%
Current month+5.45%
1 month+13.69%
3 months+12.48%
6 months+2.60%
Current year+5.69%
1 week 77.95
Extreme 77.95
84
1 month 72.3
Extreme 72.3
84
Current year 68.9
Extreme 68.9
86.74
1 year 40.03
Extreme 40.03
86.74
3 years 23.95
Extreme 23.95
86.74
5 years 23.95
Extreme 23.95
86.74
10 years 23.9
Extreme 23.9
86.74
Manager TitleAgeSince
Investor Relations Contact 60 2012-06-30
Chief Executive Officer 64 2019-12-31
Director of Finance/CFO 64 2000-04-30
Director TitleAgeSince
Director/Board Member 64 2005-12-12
Director/Board Member 73 2002-04-30
Director/Board Member 64 2019-03-24
Date Insider Type Main position Quantity % Market Cap.
06-25Sell

General Counsel

-3,069 0.0019%
06-25Fiscal year

Founder

150,000 0.0908%
06-25Fiscal year

Chief Operating Officer

78,000 0.0472%
Change 5-day change 1-year change 3-year change Capi.($)
+2.31%+3.62%+100.12%+100.22% 13.52B
+1.08%+7.56%+4.01%+9.84% 49.92B
-0.16%-1.74%+416.13%+622.39% 40.23B
-0.21%+6.90%+27.18%-5.07% 34.55B
+4.22%+6.98%+28.73%+63.77% 33.09B
-4.19%+6.03%+3.76%+32.17% 27.51B
-1.57%+2.48% - - 17.05B
+0.45%+4.42%+75.08%+138.62% 15.92B
-0.95%+0.76%+13.97%+21.59% 13.86B
-4.52%+54.74%+1,795.59%+732.69% 13.31B
Average -0.44%+11.12%+273.84%+190.69% 25.9B
Weighted average by Cap. -0.15%+9.17%+188.41%+173.47%

Financials

2026 *2027 *
Net sales 893M 782M 721M 669M 1.27B 85.22B 1.29B 8.63B 3.36B 41.83B 3.36B 3.28B 145B 1.51B 1.32B 1.21B 1.13B 2.14B 144B 2.17B 14.53B 5.66B 70.47B 5.65B 5.53B 244B
Net income -598M -524M -483M -448M -851M -57.08B -862M -5.78B -2.25B -28.02B -2.25B -2.2B -97.15B -199M -174M -160M -149M -282M -18.94B -286M -1.92B -746M -9.3B -746M -729M -32.23B
Net Debt -220M -193M -177M -165M -313M -20.99B -317M -2.12B -827M -10.3B -826M -808M -35.72B -138M -121M -111M -103M -196M -13.18B -199M -1.33B -519M -6.47B -519M -507M -22.43B
Logo Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Employees
1,402
Date Price Change Volume
26-07-06 US$83.63 +2.24% 888,501
26-07-02 US$81.80 +3.30% 2,301,899
26-07-01 US$79.19 -0.13% 1,442,398
26-06-30 US$79.29 -1.74% 2,380,302
26-06-29 US$80.69 -0.60% 2,806,623
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
81.80USD
Average target price
105.91USD
Spread / Average Target
+29.48%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IONS Stock